Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 14 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLCStatus unknownNCT04094909Phase 2 Report a problem
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung CancerActive, not recruitingNCT04093167Phase 2/3 Report a problem
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsActive, not recruitingNCT04083599Phase 1/2 Report a problem
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)Active, not recruitingNCT04079166Phase 2 Report a problem
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain MetastasisActive, not recruitingNCT04074096Phase 2 Report a problem
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaTerminatedNCT04060342Phase 1 Report a problem
Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic CancerWithdrawnNCT04058964Phase 2 Report a problem
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell CarcinomaWithdrawnNCT04058145Phase 2 Report a problem
A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic MesotheliomaCompletedNCT04056026Early Phase 1 Report a problem
The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.WithdrawnNCT04045730Phase 2 Report a problem
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)Active, not recruitingNCT04044859Phase 1 Report a problem
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerActive, not recruitingNCT04042701Phase 1 Report a problem
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsActive, not recruitingNCT04041310Phase 1/2 Report a problem
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast CancerStatus unknownNCT04024800Phase 2 Report a problem
The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic MelanomaStatus unknownNCT04017897Phase 2 Report a problem
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)TerminatedNCT04009681Phase 1/2 Report a problem
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT04007744Phase 1 Report a problem
Anti-PD-1 +/- RT for MSI-H Solid TumorsWithdrawnNCT04001101Phase 2 Report a problem
Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung CancerActive, not recruitingNCT03991819Phase 1 Report a problem
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03978689Phase 1 Report a problem
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLCActive, not recruitingNCT03970746Phase 1/2 Report a problem
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid TumorsCompletedNCT03954067Phase 1 Report a problem
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBCTerminatedNCT03952325Phase 2 Report a problem
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional TherapyCompletedNCT03941262Phase 1 Report a problem
Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCCCompletedNCT03939975Phase 2 Report a problem
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract CancerCompletedNCT03937895Phase 1/2 Report a problem
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based ChemotherapyWithdrawnNCT03935347Phase 2 Report a problem
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and LymphomaCompletedNCT03934814Phase 1 Report a problem
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic MalignanciesCompletedNCT03922204Phase 1 Report a problem
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)CompletedNCT03918278Phase 1 Report a problem
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)Active, not recruitingNCT03897881Phase 2 Report a problem
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1 Report a problem
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic MelanomaCompletedNCT03875079Phase 1 Report a problem
First-in-Human Study of EOS100850 (Inupadenant) in Patients with CancerCompletedNCT03873883Phase 1 Report a problem
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT03873025Phase 1/2 Report a problem
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsCompletedNCT03872947Phase 1 Report a problem
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic AdenocarcinomaCompletedNCT03871959Phase 1 Report a problem
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)CompletedNCT03861793Phase 1/2 Report a problem
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaActive, not recruitingNCT03854474Phase 1/2 Report a problem
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCompletedNCT03849469Phase 1 Report a problem
A Study to Evaluate Immunotherapy Combinations in Participants With Lung CancerCompletedNCT03846310Phase 1 Report a problem
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsCompletedNCT03841110Phase 1 Report a problem
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid TumorsActive, not recruitingNCT03836352Phase 2 Report a problem
AO-176 in Multiple Solid Tumor MalignanciesCompletedNCT03834948Phase 1/2 Report a problem
Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR StudyWithdrawnNCT03832673Phase 2 Report a problem
Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab TreatmentCompletedNCT03832348Not applicable Report a problem
Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) EffectCompletedNCT03825510Phase 2 Report a problem
Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PIIStatus unknownNCT03818893Phase 2 Report a problem
RPTR-147 in Patients With Selected Solid Tumors and LymphomasTerminatedNCT03815682Phase 1 Report a problem
A Study of PD1 Combined With Dc-cik in the Treatment of Solid TumorsStatus unknownNCT03815630Early Phase 1 Report a problem
A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid TumorsStatus unknownNCT03815084Early Phase 1 Report a problem
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPCActive, not recruitingNCT03813394Phase 1/2 Report a problem
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerTerminatedNCT03809624Phase 1 Report a problem
A Study of ASP1951 in Subjects With Advanced Solid TumorsTerminatedNCT03799003Phase 1 Report a problem
Vaccination With Flt3L, Radiation, and Poly-ICLCCompletedNCT03789097Phase 1/2 Report a problem
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerTerminatedNCT03786081Phase 1/2 Report a problem
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruitingNCT03785249Phase 1/2 Report a problem
A Study to Evaluate MIV-818 in Patients With Liver Cancer ManifestationsCompletedNCT03781934Phase 1/2 Report a problem
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed TumorsCompletedNCT03775850Phase 1 Report a problem
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung CancerActive, not recruitingNCT03774732Phase 3 Report a problem
MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell CarcinomaWithdrawnNCT03773744Phase 1 Report a problem
Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)Active, not recruitingNCT03772899Phase 1 Report a problem
Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum RegimenStatus unknownNCT03771820Phase 2 Report a problem
Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or MetastasesCompletedNCT03757858Phase 1/2 Report a problem
Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)CompletedNCT03752723Phase 1/2 Report a problem
A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal CarcinomaStatus unknownNCT03736330Phase 2 Report a problem
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced CancerTerminatedNCT03735290Phase 1 Report a problem
CART-EGFRvIII + Pembrolizumab in GBMCompletedNCT03726515Phase 1 Report a problem
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric CancerCompletedNCT03724851Phase 1/2 Report a problem
TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent GlioblastomaStatus unknownNCT03722342Phase 1 Report a problem
Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1TerminatedNCT03721679Phase 1/2 Report a problem
TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast CancerStatus unknownNCT03720431Phase 1 Report a problem
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung AdenocarcinomaStatus unknownNCT03709147Phase 2 Report a problem
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1aWithdrawnNCT03697824Phase 2 Report a problem
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC AdenocarcinomaTerminatedNCT03696212Phase 1/2 Report a problem
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsActive, not recruitingNCT03693014Phase 2 Report a problem
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid TumorsTerminatedNCT03684785Phase 1/2 Report a problem
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.CompletedNCT03666273Phase 1 Report a problem
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing GlioblastomaCompletedNCT03665545Phase 1/2 Report a problem
Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal CancerCompletedNCT03658772Phase 1 Report a problem
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)CompletedNCT03658447Phase 1/2 Report a problem
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsActive, not recruitingNCT03647163Phase 1/2 Report a problem
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsTerminatedNCT03645928Phase 2 Report a problem
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid TumorsTerminatedNCT03637803Phase 1/2 Report a problem
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDACStatus unknownNCT03634332Phase 2 Report a problem
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted VaccineCompletedNCT03633110Phase 1/2 Report a problem
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsActive, not recruitingNCT03611868Phase 1/2 Report a problem
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast CancerCompletedNCT03599453Early Phase 1 Report a problem
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)TerminatedNCT03598608Phase 1/2 Report a problem
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal CancerWithdrawnNCT03592407Phase 2 Report a problem
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesCompletedNCT03590054Phase 1 Report a problem
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyActive, not recruitingNCT03589339Phase 1 Report a problem
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid TumorsTerminatedNCT03588039Phase 1 Report a problem
CTA Expression/Methylation and Response to Pembrolizumab of NSCLC PatientsStatus unknownNCT03571360Phase 2 Report a problem
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBCActive, not recruitingNCT03567720Phase 2 Report a problem
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid TumorsCompletedNCT03565445Phase 1 Report a problem
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)CompletedNCT03564691Phase 1 Report a problem
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLCCompletedNCT03562871Phase 1/2 Report a problem
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingNCT03547973Phase 2 Report a problem
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior TherapiesActive, not recruitingNCT03546426Phase 1 Report a problem

← Pembrolizumab